EASY BIO,Inc. (353810.KQ)
KRW 4570.0
(0.44%)
KRW 4570.0
(0.44%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 24.32 Billion KRW | 25.54% |
| 2022 | 16.77 Billion KRW | -2.51% |
| 2021 | 17.84 Billion KRW | 15.08% |
| 2020 | 15.53 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 9.72 Billion KRW | 38.81% |
| 2024 Q1 | 7.38 Billion KRW | 26.25% |
| 2023 Q1 | 7.09 Billion KRW | 63.11% |
| 2023 FY | - KRW | 25.54% |
| 2023 Q4 | 5.84 Billion KRW | -15.28% |
| 2023 Q3 | 6.9 Billion KRW | 2.77% |
| 2023 Q2 | 6.71 Billion KRW | -5.35% |
| 2022 FY | - KRW | -2.51% |
| 2022 Q3 | 5.53 Billion KRW | 19.83% |
| 2022 Q4 | 4.35 Billion KRW | -21.34% |
| 2022 Q2 | 4.61 Billion KRW | -3.55% |
| 2022 Q1 | 4.78 Billion KRW | 2.15% |
| 2021 Q1 | 5.45 Billion KRW | 13.46% |
| 2021 FY | - KRW | 15.08% |
| 2021 Q4 | 4.68 Billion KRW | -3.08% |
| 2021 Q3 | 4.83 Billion KRW | 0.63% |
| 2021 Q2 | 4.8 Billion KRW | -11.98% |
| 2020 FY | - KRW | 0.0% |
| 2020 Q4 | 4.81 Billion KRW | -31.18% |
| 2020 Q3 | 6.98 Billion KRW | 77.34% |
| 2020 Q2 | 3.94 Billion KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Co., Ltd. | -172.27 Billion KRW | 114.119% |
| iNtRON Biotechnology, Inc. | -6.23 Billion KRW | 490.13% |
| BINEX Co., Ltd. | 10.87 Billion KRW | -123.723% |
| Bioneer Corporation | 10.04 Billion KRW | -142.186% |
| Anterogen.Co.,Ltd. | -437.82 Million KRW | 5655.476% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | 225.431% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | 156.834% |
| Helixmith Co., Ltd | -53 Billion KRW | 145.889% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | 65.296% |
| Medy-Tox Inc. | 32.69 Billion KRW | 25.613% |
| Peptron, Inc. | -12.65 Billion KRW | 292.271% |
| Amicogen, Inc. | 13.95 Billion KRW | -74.321% |
| Genexine, Inc. | -40.87 Billion KRW | 159.502% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | -195.558% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | 134.073% |
| ALTEOGEN Inc. | 440.04 Million KRW | -5427.483% |
| PharmaResearch Co., Ltd. | 104.25 Billion KRW | 76.669% |
| SillaJen, Inc. | -17.35 Billion KRW | 240.172% |
| JETEMA, Co., Ltd. | 11 Billion KRW | -120.964% |
| OliX Pharmaceuticals,Inc | -11.13 Billion KRW | 318.438% |
| Genomictree Inc. | -6.33 Billion KRW | 484.142% |
| MedPacto, Inc. | -32.6 Billion KRW | 174.592% |
| D&D Pharmatech | -9.05 Billion KRW | 368.531% |
| GI Innovation, Inc. | -51.33 Billion KRW | 147.386% |